Storia in 2 fonti

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026

Raccontata da

morningstar.com

healio.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

morningstar.comStai leggendo1 mesi fa

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026

originale

healio.com1 mesi fa

Add-on ralinepag delays first clinical worsening event in PAH

ORLANDO — Ralinepag, a prostacyclin receptor agonist, added to background therapy decreased the risk for a clinical worsening event in patients with pulmonary arterial hypertension, according to phase 3 ADVANCE OUTCOMES…

Leggi questa versione → originale

Timeline cronologica

domenica 17 maggio 2026·morningstar.com
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
martedì 19 maggio 2026·healio.com
Add-on ralinepag delays first clinical worsening event in PAH
ORLANDO — Ralinepag, a prostacyclin receptor agonist, added to background therapy decreased the risk for a clinical worsening event in patients with pulmonary arterial…